ReGenX Biosciences: Annual Report 2015 (Regenxbio) - Mar 19, 2016 - Anticipated expiry of patents related to AAV8 vectors and uses in US from 2022 to 2026; Anticipated patent expiry in Europe related to AAV8 vectors in 2022
Anticipated patent expiry • Hemophilia
|